Document Type


Journal/Book Title/Conference

Synthesis of kurasoin B analogs

Publication Date



Kurasoin B (1), isolated in 1996 by Uchida et al, selectively inhibits Farnesyltransferase (FTase), an enzyme responsible for activating human RAS proteins (ref. 1). When RAS proteins are mutated and then activated, they contribute 20 to 30 percent of all human tumors, including those of the pancreas, colon, small intestine, lung, prostate, liver, skin, and thyroid, as well as multiple myeloma and a number of leukemias (ref. 2). Kurasoin B, therefore, has great potential as a cancer drug lead.


Abstracts of Papers, 236th ACS National Meeting, Salt Lake City, UT, United States, April 22-26, 2009. Poster.

Also available in PDF.

Additional Files

2009 ACS Poster (Kurasoin B Analogs).pdf (808 kB)